These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


228 related items for PubMed ID: 23936477

  • 1. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
    Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF.
    PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
    [Abstract] [Full Text] [Related]

  • 2. Glucuronidation of trans-3'-hydroxycotinine by UGT2B17 and UGT2B10.
    Chen G, Giambrone NE, Lazarus P.
    Pharmacogenet Genomics; 2012 Mar; 22(3):183-90. PubMed ID: 22228205
    [Abstract] [Full Text] [Related]

  • 3. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.
    Chen G, Giambrone NE, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, Lazarus P.
    Cancer Res; 2010 Oct 01; 70(19):7543-52. PubMed ID: 20876810
    [Abstract] [Full Text] [Related]

  • 4. The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.
    Bloom AJ, von Weymarn LB, Martinez M, Bierut LJ, Goate A, Murphy SE.
    Pharmacogenet Genomics; 2013 Dec 01; 23(12):706-16. PubMed ID: 24192532
    [Abstract] [Full Text] [Related]

  • 5. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
    Murphy SE, Sipe CJ, Choi K, Raddatz LM, Koopmeiners JS, Donny EC, Hatsukami DK.
    Cancer Epidemiol Biomarkers Prev; 2017 Jul 01; 26(7):1093-1099. PubMed ID: 28264876
    [Abstract] [Full Text] [Related]

  • 6. Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.
    Taghavi T, St Helen G, Benowitz NL, Tyndale RF.
    Pharmacogenet Genomics; 2017 Apr 01; 27(4):143-154. PubMed ID: 28178031
    [Abstract] [Full Text] [Related]

  • 7. Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
    Giratallah HK, Chenoweth MJ, Addo N, Ahluwalia JS, Cox LS, Lerman C, George TP, Benowitz NL, Tyndale RF.
    Drug Alcohol Depend; 2021 Jun 01; 223():108708. PubMed ID: 33873029
    [Abstract] [Full Text] [Related]

  • 8. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.
    Wassenaar CA, Conti DV, Das S, Chen P, Cook EH, Ratain MJ, Benowitz NL, Tyndale RF.
    Cancer Epidemiol Biomarkers Prev; 2015 Jan 01; 24(1):94-104. PubMed ID: 25277794
    [Abstract] [Full Text] [Related]

  • 9. Effect of race and glucuronidation rates on the relationship between nicotine metabolite ratio and nicotine clearance.
    Liakoni E, Tyndale RF, Jacob P, Dempsey DA, Addo N, Benowitz NL.
    Pharmacogenet Genomics; 2021 Jul 01; 31(5):97-107. PubMed ID: 33675323
    [Abstract] [Full Text] [Related]

  • 10. Interindividual variability in nicotine metabolism: C-oxidation and glucuronidation.
    Nakajima M, Yokoi T.
    Drug Metab Pharmacokinet; 2005 Aug 01; 20(4):227-35. PubMed ID: 16141602
    [Abstract] [Full Text] [Related]

  • 11. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.
    Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF.
    Clin Pharmacol Ther; 2009 Jun 01; 85(6):635-43. PubMed ID: 19279561
    [Abstract] [Full Text] [Related]

  • 12. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.
    Berg JZ, von Weymarn LB, Thompson EA, Wickham KM, Weisensel NA, Hatsukami DK, Murphy SE.
    Cancer Epidemiol Biomarkers Prev; 2010 Jun 01; 19(6):1423-31. PubMed ID: 20501767
    [Abstract] [Full Text] [Related]

  • 13. Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.
    Perez-Paramo YX, Watson CJW, Chen G, Thomas CE, Adams-Haduch J, Wang R, Khor CC, Koh WP, Nelson HH, Yuan JM, Lazarus P.
    Cancer Epidemiol Biomarkers Prev; 2023 Jan 09; 32(1):54-65. PubMed ID: 36252563
    [Abstract] [Full Text] [Related]

  • 14. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.
    Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL.
    Clin Pharmacol Ther; 2004 Jul 09; 76(1):64-72. PubMed ID: 15229465
    [Abstract] [Full Text] [Related]

  • 15. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.
    Lea RA, Dickson S, Benowitz NL.
    J Anal Toxicol; 2006 Jul 09; 30(6):386-9. PubMed ID: 16872570
    [Abstract] [Full Text] [Related]

  • 16. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.
    Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE.
    J Pharmacol Exp Ther; 2010 Jan 09; 332(1):202-9. PubMed ID: 19786624
    [Abstract] [Full Text] [Related]

  • 17. A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.
    Taghavi T, Novalen M, Lerman C, George TP, Tyndale RF.
    Cancer Epidemiol Biomarkers Prev; 2018 Aug 09; 27(8):882-891. PubMed ID: 29853480
    [Abstract] [Full Text] [Related]

  • 18. Carbamazepine but not valproate induces CYP2A6 activity in smokers with mental illness.
    Williams JM, Gandhi KK, Benowitz NL.
    Cancer Epidemiol Biomarkers Prev; 2010 Oct 09; 19(10):2582-9. PubMed ID: 20719908
    [Abstract] [Full Text] [Related]

  • 19. Relationship between cotinine and trans-3'-hydroxycotinine glucuronidation and the nicotine metabolite ratio in Caucasian smokers.
    Jacobson GA, Ferguson SG.
    Biomarkers; 2014 Dec 09; 19(8):679-83. PubMed ID: 25373622
    [Abstract] [Full Text] [Related]

  • 20. Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation.
    Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, Tyndale RF.
    Cancer Epidemiol Biomarkers Prev; 2015 Aug 09; 24(8):1239-46. PubMed ID: 26014804
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 12.